Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update
Cannabis Law Report
NOVEMBER 12, 2021
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. ” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. ANEB-001 has been shown to antagonize THC-induced hypolocomotion in mice, a CB1 receptor-mediated response.
52 
Let's personalize your content